Durvalumab-induced thyroiditis in a patient with non-small cell lung carcinoma: a case report and review of pathogenic mechanisms

Durvalumab-induced thyroiditis in a patient with non-small cell lung carcinoma: a case report and review of pathogenic mechanisms

Abstract Background Immune checkpoint inhibitors (ICI) targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 and its ligand (PD-1/PD-L1) have become the current standard-of-care for advanced cancers. This novel therapeutic approach comes with its costs in th...

Full description

Bibliographic Details
Main Authors: Jeroen M. K. de Filette, Stéphanie André, Lynn De Mey, Sandrine Aspeslagh, Rafik Karmali, Bart J Van der Auwera, Bert Bravenboer
Format: Article
Language:English
Published: BMC 2022-11-01
Series:BMC Endocrine Disorders
Subjects:
Durvalumab
Thyroiditis
Immune Checkpoint Inhibitors
HLA
Case Report
Online Access:https://doi.org/10.1186/s12902-022-01190-5

Internet

https://doi.org/10.1186/s12902-022-01190-5

Similar Items